Purpose: This study will evaluate how measurements of tissue stiffness, viscosity, and anisotropy using non-invasive ultrasound imaging correlate with breast tumor malignancy and response to chemotherapy. Participants: Up to 200 women with benign or malignant breast tumors for arm 1 and up to 50 women undergoing neoadjuvant chemotherapy in the breast for arm 2 will be recruited. Procedures (methods): The research team will use an ultrasound scanner to acquire non-invasive elastography data from the breast of each subject, testing a range of transducer rotation angles. Transducer position will be monitored using a position sensor during imaging.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
ARFI Peak Displacement (PD) in lesion (Study Arm 1)
Timeframe: Baseline imaging
ARFI Peak Displacement (PD) in surrounding tissue (Study Arm 1)
Timeframe: Baseline imaging
VisR Relative Elasticity (RE) in lesion (Study Arm 1)
Timeframe: Baseline imaging
VisR Relative Elasticity (RE) in surrounding tissue (Study Arm 1)
Timeframe: Baseline imaging
VisR Relative Viscosity (RV) in lesion (Study Arm 1)
Timeframe: Baseline imaging
VisR Relative Viscosity (RV) in surrounding tissue (Study Arm 1)
Timeframe: Baseline imaging
ARFI PD DoA in lesion (Study Arm 1)
Timeframe: Baseline imaging
ARFI PD DoA in surrounding tissue (Study Arm 1)
Timeframe: Baseline imaging
VisR RE DoA in lesion (Study Arm 1)
Timeframe: Baseline imaging
VisR RE DoA in surrounding tissue (Study Arm 1)
Timeframe: Baseline imaging
VisR RV DoA in lesion (Study Arm 1)
Timeframe: Baseline imaging
VisR RV DoA in surrounding tissue (Study Arm 1)
Timeframe: Baseline imaging
ARFI Peak Displacement (PD) in lesion (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
ARFI Peak Displacement (PD) in surrounding tissue (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
VisR Relative Elasticity (RE) in lesion (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
VisR Relative Elasticity (RE) in surrounding tissue (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
VisR Relative Viscosity (RV) in lesion (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
VisR Relative Viscosity (RV) in surrounding tissue (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
ARFI PD DoA in lesion (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
ARFI PD DoA in surrounding tissue (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
VisR RE DoA in lesion (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
VisR RE DoA in surrounding tissue (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
VisR RV DoA in lesion (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months
VisR RV DoA in surrounding tissue (Study Arm 2)
Timeframe: From enrollment to end of neoadjuvant systemic therapy, assessed up to 8 months